Article Text

PDF
Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS)
  1. P Hjemdahl1,
  2. S V Eriksson2,
  3. C Held3,
  4. L Forslund4,
  5. P Näsman5,
  6. N Rehnqvist6
  1. 1Department of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital (Solna), Stockholm, Sweden
  2. 2Department of Internal Medicine, Karolinska Institutet at Danderyd Hospital, Danderyd, Sweden
  3. 3Department of Medicine, Cardiology Unit, Karolinska University Hospital, Stockholm, Sweden
  4. 4Medical Products Agency, Uppsala, Sweden
  5. 5Royal Institute of Technology, Stockholm, Sweden
  6. 6Swedish Council on Technology Assessment in Health Care (SBU), Stockholm, Sweden
  1. Correspondence to:
    Dr Paul Hjemdahl
    Department of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital (Solna), SE-171 76 Stockholm, Sweden; Paul.Hjemdahl{at}medks.ki.se

Abstract

Objective: To evaluate the long term prognosis of patients with stable angina pectoris.

Design: Registry based follow up (median 9.1 years) of patients participating in the APSIS (angina prognosis study in Stockholm), which was a double blind, single centre trial of antianginal drug treatment.

Patients: 809 patients (31% women) with stable angina pectoris < 70 (mean (SD) 59 (7) years at inclusion) and an age and sex matched reference population from the same catchment area.

Interventions: Double blind treatment with metoprolol or verapamil during 3.4 years (median), followed by referral for usual care with open treatment.

Main outcome measures: Cardiovascular (CV) death and non-fatal myocardial infarction (MI) in the APSIS cohort and total mortality in comparison with reference subjects.

Results: 123 patients died (41 MI, 36 other CV causes) and 72 had non-fatal MI. Mortality (19% v 6%, p<0.001) and fatal MI (6.6% v 1.6%, p < 0.001) were increased among male compared with female patients. Diabetes, previous MI, hypertension, and male sex independently predicted CV mortality (p < 0.001). Diabetes greatly increased the risk in a small subgroup of female patients. Male patients had higher mortality than men in the reference population during the first three years (cumulative absolute difference 3.8%) but apparently not thereafter. Female patients had similar mortality to women in the reference population throughout the 9.1 years of observation.

Conclusions: Female patients with stable angina had similar mortality to matched female reference subjects but male patients had an increased risk. Diabetes, previous MI, hypertension, and male sex were strong risk factors for CV death or MI.

  • ACTION, a coronary disease trial investigating outcome with nifedipine gastrointestinal therapeutic system
  • APSIS, angina prognosis study in Stockholm
  • CCS, Canadian Cardiovascular Society
  • CV, cardiovascular
  • ICD-9, International classification of diseases, ninth revision
  • INVEST, international verapamil-trandolapril study
  • MI, myocardial infarction
  • RITA-2, second randomized intervention treatment of angina
  • SAPAT, Swedish low dose aspirin trial
  • TIBET, total ischaemic burden European trial
  • stable angina pectoris
  • death
  • myocardial infarction
  • sex differences
  • diabetes mellitus

Statistics from Altmetric.com

Footnotes

  • Published Online First 10 June 2005

  • Conflicts of interest: none

  • The study was presented in preliminary form at the Scientific Sessions of the American Heart Association (abstract 2688), 2003.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.